Dr. Daniel Friedman discusses surgical ablation of atrial fibrillation with Dr. Marc Gillinov

Dr. Daniel Friedman talks with Dr. Marc Gillinov of the Cleveland Clinic about h, a study that randomized patients undergoing mitral valve surgery to atrial fibrillation ablation and left atrial appendage ligation or no ablation. The study concluded that atrial fibrillation ablation improves rhythm control in patients undergoing cardiac surgery, though more patients undergoing ablation required permanent pacemaker placement. The study did not look at clinical outcomes beyond rhythm control.

Dr. Tiffany Randolph discusses the economic analysis of PROMISE with Dr. Daniel Mark

Dr. Tiffany Randolph talks with Dr. Daniel Mark of the DCRI about an economic analysis of the PROMISE trial presented at ACC.15. PROMISE did not show a difference in outcomes between groups randomized to CT coronary angiography and usual care, and cost of care was equivalent between the groups, as the lower cost of CT coronary angiography was counterbalanced by a higher rate of invasive procedures in this group.

Dr. Matthew Sherwood discusses his poster on the use of apixaban after ACS in patients with prior stroke

Dr. Matthew Sherwood, a fellow at the DCRI, talks about his poster, which used data from APPRAISE-2 to examine the effect of treatment with apixaban after acute coronary syndrome in patients with prior stroke. He concludes that treatment with apixaban after an acute coronary syndrome does not reduce the risk of cardiovascular outcomes in patients with a prior stroke, though it may have a beneficial effect in the subset of patients without prior stroke.

Dr. Amit Vora discusses five-year results from the PARTNER trial with Dr. Pamela Douglas

Dr. Amit Vora talks with Dr. Pamela Douglas of the DCRI about five-year outcomes from the high-risk cohort of the PARTNER trial, which compared transcutaneous aortic valve replacement (TAVR) with surgical aortic valve replacement (SAVR). Similar to data previously presented about three-year outcomes in PARTNER, five-year outcomes were equivalent between the groups for mortality, cardiovascular mortality, stroke, and hospitalization.

Dr. Jacob Kelly discusses REGULATE PCI with Dr. John Alexander

Dr. Jacob Kelly speaks with Dr. John Alexander of the DCRI about REGULATE PCI, a study comparing use of a new anticoagulant system, REG-1, to bivalrudin in patients undergoing percutaneous intervention. REG-1 is comprised of an anticoagulant, pegnivacogin, and an RNA aptamer, anivamersen, that is able to block to pegnivacogin’s activity if necessary. The trial was stopped early due to safety concerns regarding allergic reactions in patients receiving REG-1.